Watch TARS. Know when insiders buy.
One email the day a filing lands. Free.
TARS
Tarsus Pharmaceuticals, Inc.
71.53
+0.50 +0.70%
USD · close Oct 21
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
37
FLAG · insiders 25, shorts 49
Insiders, 90 days
−$5.2M
net selling · 0 buys, 14 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.1BP/E —DIV YIELD —FCF YIELD 1.78%REV TTM $606.3M +105.2%NET INCOME −$46.5MNET CASH $131.8M52W 56.11 – 90.78SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $173.9M | +69.4% | 93.0% | −$19.9M | −$18.6M | — | -0.43 | $61.2M | $4.1M | $57.2M | Aug 6 |
| Q1 2026 · Mar 31 | $162.1M | +106.9% | 94.2% | −$6.1M | −$7M | — | -0.16 | −$24.7M | $5.8M | −$30.5M | Aug 6 |
| Q4 2025 · Dec 31derived | $151.7M | +128.4% | — | −$8M | −$8.4M | — | -0.19 | $19.3M | $6.4M | $13M | Feb 23 |
| Q3 2025 · Sep 30 | $118.7M | +146.7% | — | −$14.5M | −$12.6M | — | -0.30 | $18.3M | $1.9M | $16.3M | Nov 4 |
| Q2 2025 · Jun 30 | $102.7M | +151.5% | 93.9% | −$22.2M | −$20.3M | — | -0.48 | −$29.4M | $1M | −$30.4M | Aug 6 |
| Q1 2025 · Mar 31 | $78.3M | +183.7% | 93.3% | −$26.3M | −$25.1M | — | -0.64 | −$20.7M | $590K | −$21.2M | Aug 6 |
| Q4 2024 · Dec 31derived | $66.4M | +407.9% | — | −$24.4M | −$23.1M | — | -0.59 | −$22.2M | $72K | −$22.3M | Feb 23 |
| Q3 2024 · Sep 30 | $48.1M | +2471.8% | — | −$25.2M | −$23.4M | — | -0.61 | −$8.7M | $282K | −$8.9M | Nov 4 |
| Q2 2024 · Jun 30 | $40.8M | — | — | −$33.3M | −$33.3M | — | -0.88 | −$14.4M | $1M | −$15.4M | Nov 4 |
| Q1 2024 · Mar 31 | $27.6M | — | — | −$37.7M | −$35.7M | — | -1.01 | −$37.8M | $174K | −$38M | Nov 4 |
| Q4 2023 · Dec 31derived | $13.1M | — | — | −$44.5M | −$41.9M | — | -1.27 | −$39.3M | $0 | −$39.3M | Feb 23 |
| Q3 2023 · Sep 30 | $1.9M | — | — | −$40.9M | −$39.1M | — | -1.28 | −$32.4M | $375K | −$32.7M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $451.4M | — | −$71M | −$66.4M | -14.7% | -1.59 | −$12.5M | $9.9M | −$22.3M | — | — |
| FY2024 · to Dec 31 | $183M | — | −$120.6M | −$115.6M | -63.2% | -3.07 | −$83M | $1.6M | −$84.6M | — | — |
| FY2023 · to Dec 31 | $17.4M | — | −$143.2M | −$135.9M | -778.9% | -4.62 | −$117.5M | $1.5M | −$119M | — | — |
| FY2022 · to Dec 31 | $25.8M | — | −$62.7M | −$62.1M | -240.5% | -2.52 | −$49M | $506K | −$49.5M | — | — |
| FY2021 · to Dec 31 | $57M | — | −$12.2M | −$13.8M | -24.2% | -0.67 | $3.7M | $586K | $3.2M | — | — |
| FY2020 · to Dec 31 | $0 | — | −$27M | −$26.8M | — | -4.32 | −$21.1M | $456K | −$21.6M | — | — |
Every number comes from Tarsus Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.